- You are here: Home
- Disease Models
- Neurological Disease Models
- Alzheimer's Disease Modeling and Assays
- Alzheimer's Disease In Vitro Model Service
Disease Models
- Oncology Models
-
Inflammation & Autoimmune Disease Models
- Rheumatoid Arthritis Models
- Glomerulonephritis Models
- Multiple Sclerosis (MS) Models
- Ocular Inflammation Models
- Sjögren's Syndrome Model
- LPS-induced Acute Lung Injury Model
- Peritonitis Models
- Passive Cutaneous Anaphylaxis Model
- Delayed-Type Hypersensitivity (DTH) Models
- Inflammatory Bowel Disease Models
- Systemic Lupus Erythematosus Animal Models
- Asthma Model
- Sepsis Model
- Psoriasis Model
- Atopic Dermatitis (AD) Model
- Scleroderma Model
- Gouty Arthritis Model
- Carrageenan-Induced Air Pouch Synovitis Model
- Carrageenan-Induced Paw Edema Model
- Experimental Autoimmune Myasthenia Gravis (EAMG) Model
- Cardiovascular Disease Models
-
Neurological Disease Models
- Alzheimer's Disease Modeling and Assays
- Seizure Models
- Parkinson's Disease Models
- Ischemic Stroke Models
- Acute Spinal Cord Injury (ASCI) Model
- Traumatic Brain Injury (TBI) Model
- Hypoxic-Ischemic Encephalopathy (HIE) Model
- Tourette Syndrome (TS) Model
- Amyotrophic Lateral Sclerosis (ALS) Model
- Huntington's Disease (HD) Model
- Intracerebral hemorrhage (ICH) Models
- Pain Models
- Metabolic Disease Models
- Liver Disease Models
- Rare Disease Models
- Respiratory Disease Models
- Digestive Disease Models
-
Urology Disease Models
- Cisplatin-induced Nephrotoxicity Model
- Unilateral Ureteral Obstruction Model
- 5/6 Nephrectomy Model
- Renal Ischemia-Reperfusion Injury (RIRI) Model
- Diabetic Nephropathy (DN) Models
- Passive Heymann Nephritis (PHN) Model
- Adenine-Induced Chronic Kidney Disease (CKD) Model
- Kidney Stone Model
- Doxorubicin-Induced Nephropathy Model
- Orthopedic Disease Models
- Ocular Disease Models
Alzheimer's Disease In Vitro Model Service
Creative Bioarray offers development of custom designed in vitro models by using primary neuronal cultures, cell lines, iPS cells with genetic modifications, which are phenotypically closer to the adult neuronal network and mimic the development of AD. Our custom model services focus on but not restricted to AD induced by the accumulation and aggregation of Aβ. We also offer a wide range of assays that enable more accurate prediction of patient response to pharmacotherapy:
- Aβ induced neurotoxicity assay
- Amyloid β (Aβ) peptide aggregation inhibition assay
- Aβ peptide formation or screening for secretase inhibitors
- APP Processing Assay
- Beta secretase inhibitors
- Gamma secretase inhibitors
- Inhibitors of Aβ peptide formation
- Tau hyperphosphorylation assay
- Tau aggregation assay
- Neurite outgrowth assay
We provide this powerful and versatile tool for AD therapy as well as basic research to help our customers understand more about the underlying mechanisms in the progression of AD.
Study Example
Figure 1 Neurite outgrowth is inhibited by (intracellular) amyloid and tau treatment, and rescued by β-secretase inhibitor and methylene blue respectively.
Quotation and ordering
Contact us if you have any questions. Our customer service representatives are available 24hr a day.
Reference
- Stoppelkamp, S.; et al. In vitro modelling of Alzheimer's disease: degeneration and cell death induced by viral delivery of amyloid and tau. Experimental neurology. 2011, 229(2): 226-237.
For research use only. Not for any other purpose.
